Ophthalmology Solution Articles & Analysis
3 news found
Approximately 70% of Subjects were Well-Controlled on iDose TR with the Same or Fewer Topical IOP-Lowering Medications at 36 Months vs. Screening Favorable Safety Profile Through 36 Months . SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the iPRIME™ Viscodelivery System, a sterile, ...
Additional awards and recognition include: President and CEO Dave Van Meter named Entrepreneur Of The Year® by Ernst & Young LLP (2020 Pacific Southwest-Orange County division) “Strong Recommendation” of Ivantis’ Hydrus Microstent under the American Academy of Ophthalmology’s (AAO) 2020 Primary Open-Angle Glaucoma Preferred Practice Pattern; ...